|
11 Companies |
|
6 Products |
|
6 Products |
|
17 Mechanisms of Action |
|
0 Trials |
|
66 News |
|
| «12 |
- ||| Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Enrollment closed, Metastases: A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib (clinicaltrials.gov) - May 14, 2013
P2, N=129, Active, not recruiting, Sponsor: Jennerex Biotherapeutics
Recruiting --> Active, not recruiting
- JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic
New P2 trial: Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE (clinicaltrials.gov) - Apr 7, 2013
P2, N=352, Suspended, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Trial initiation date: A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 4, 2013
P2, N=30, Completed, Sponsor: Jennerex Biotherapeutics
Recruiting --> Active, not recruiting Initiation date: Apr 2008 --> Aug 2008
- Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Enrollment change, Metastases: A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma (clinicaltrials.gov) - Mar 4, 2013
P1/2, N=10, Completed, Sponsor: Jennerex Biotherapeutics
Initiation date: Apr 2008 --> Aug 2008 N=15 --> 10
- Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Enrollment closed: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors (clinicaltrials.gov) - Feb 14, 2013
P1, N=23, Active, not recruiting, Sponsor: Jennerex Biotherapeutics
N=15 --> 10 Completed --> Active, not recruiting
- | Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Trial completion: A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 13, 2013
P2, N=30, Completed, Sponsor: Jennerex Biotherapeutics
Completed --> Active, not recruiting Active, not recruiting --> Completed
- Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Enrollment change: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients (clinicaltrials.gov) - Feb 12, 2013
P1, N=6, Active, not recruiting, Sponsor: Jennerex Biotherapeutics
Active, not recruiting --> Completed N=15 --> 6
- Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Enrollment closed, Metastases: Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma (clinicaltrials.gov) - Feb 12, 2013
P1, N=15, Active, not recruiting, Sponsor: Jennerex Biotherapeutics
N=15 --> 6 Completed --> Active, not recruiting
- | Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Enrollment closed: A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 12, 2013
P2, N=25, Active, not recruiting, Sponsor: Jennerex Biotherapeutics
Completed --> Active, not recruiting Completed --> Active, not recruiting
- Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Enrollment closed: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients (clinicaltrials.gov) - Feb 12, 2013
P1, N=6, Active, not recruiting, Sponsor: Jennerex Biotherapeutics
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Enrollment change, Metastases: Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors (clinicaltrials.gov) - Jan 31, 2013
P2a, N=2, Terminated, Sponsor: Jennerex Biotherapeutics
Recruiting --> Active, not recruiting N=20 --> 2
- | Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Enrollment change: A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 31, 2013
P2, N=25, Active, not recruiting, Sponsor: Jennerex Biotherapeutics
N=20 --> 2 N=10 --> 25
- | New P2a trial: Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) (clinicaltrials.gov) - Oct 10, 2012
P2a, N=150, Active, not recruiting, Sponsor: National Center for AIDS/STD Control and Prevention, China CDC
- |||| JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic
Trial completion: A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE (clinicaltrials.gov) - Sep 25, 2012
P2, N=120, Completed, Sponsor: Bavarian Nordic
N=10 --> 25 Active, not recruiting --> Completed
- Trial initiation date: Safety Study of Modified Vaccinia Virus to Cancer (clinicaltrials.gov) - Sep 4, 2012
P1, N=36, Active, not recruiting, Sponsor: David Bartlett
Active, not recruiting --> Completed Initiation date: Feb 2008 --> May 2008
- Enrollment closed: Safety Study of Modified Vaccinia Virus to Cancer (clinicaltrials.gov) - Sep 4, 2012
P1, N=36, Active, not recruiting, Sponsor: David Bartlett
Initiation date: Feb 2008 --> May 2008 Recruiting --> Active, not recruiting
- JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic
Trial completion: Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects (clinicaltrials.gov) - Aug 8, 2012
P1, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Enrollment change: A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain) (clinicaltrials.gov) - Aug 1, 2012
P2, N=147, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed N=230 --> 147
- |||| Trial completion: A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain) (clinicaltrials.gov) - Aug 1, 2012
P2, N=147, Completed, Sponsor: Sanofi
N=230 --> 147 Enrolling by invitation --> Completed
- | olvimulogene nanivacirepvec (GL-ONC1) / Genelux
New P1 trial, Combination therapy, Metastases: Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer (clinicaltrials.gov) - Apr 22, 2012
P1, N=24, Recruiting, Sponsor: Genelux Corporation
- | olvimulogene nanivacirepvec (GL-ONC1) / Genelux
Trial initiation date, Oncolytic virus, Metastases: A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis (clinicaltrials.gov) - Feb 19, 2012
P1/2, N=30, Recruiting, Sponsor: Genelux GmbH
Enrolling by invitation --> Completed Initiation date: Oct 2011 --> Feb 2012
- | olvimulogene nanivacirepvec (GL-ONC1) / Genelux
Enrollment open, Oncolytic virus, Metastases: A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis (clinicaltrials.gov) - Feb 19, 2012
P1/2, N=30, Recruiting, Sponsor: Genelux GmbH
Initiation date: Oct 2011 --> Feb 2012 Not yet recruiting --> Recruiting
- JYNNEOS (live modified vaccinia virus ankara) / Bavarian Nordic
Trial completion: High Dose IMVAMUNE (clinicaltrials.gov) - Feb 15, 2012
P2, N=91, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Trial termination, Metastases: Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors (clinicaltrials.gov) - Feb 2, 2012
P2a, N=2, Terminated, Sponsor: Jennerex Biotherapeutics
Active, not recruiting --> Completed Recruiting --> Terminated
- TPOXX (tecovirimat) / SIGA Technologies
Enrollment change: SIGA-246 to Treat Smallpox (clinicaltrials.gov) - Nov 15, 2011
P1, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Terminated N=100 --> 0
- | olvimulogene nanivacirepvec (GL-ONC1) / Genelux
New P1/2 trial, Oncolytic virus, Metastases: A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis (clinicaltrials.gov) - Sep 27, 2011
P1/2, N=30, Recruiting, Sponsor: Genelux GmbH